C.H. Geisler
C.H. Geisler
department of hematology, Rigshospitalet, Copenhagen, Denmark
El. paštas nepatvirtintas
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 …
CH Geisler, A Kolstad, A Laurell, NS Andersen, LB Pedersen, ...
Blood, The Journal of the American Society of Hematology 112 (7), 2687-2693, 2008
Treatment of older patients with mantle-cell lymphoma
HC Kluin-Nelemans, E Hoster, O Hermine, J Walewski, M Trneny, ...
New England Journal of Medicine 367 (6), 520-531, 2012
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic …
T Robak, A Dmoszynska, P Solal-Céligny, K Warzocha, J Loscertales, ...
Journal of clinical oncology 28 (10), 1756-1765, 2010
An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
International CLL-IPI Working Group
The Lancet Oncology 17 (6), 779-790, 2016
Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies
A Agathangelidis, N Darzentas, A Hadzidimitriou, X Brochet, F Murray, ...
Blood, The Journal of the American Society of Hematology 119 (19), 4467-4475, 2012
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ...
The lancet oncology 16 (2), 169-176, 2015
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
CW Eskelund, C Dahl, JW Hansen, M Westman, A Kolstad, LB Pedersen, ...
Blood, The Journal of the American Society of Hematology 130 (17), 1903-1910, 2017
Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem‐cell support …
CH Geisler, A Kolstad, A Laurell, M Jerkeman, R Räty, NS Andersen, ...
British journal of haematology 158 (3), 355-362, 2012
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein–kinase–dependent mechanism
IM Pedersen, AM Buhl, P Klausen, CH Geisler, J Jurlander
Blood, The Journal of the American Society of Hematology 99 (4), 1314-1319, 2002
Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia
CH Geisler, JK Larsen, NE Hansen, MM Hansen, BE Christensen, B Lund, ...
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
M Ghielmini, U Vitolo, E Kimby, S Montoto, J Walewski, M Pfreundschuh, ...
Annals of oncology 24 (3), 561-576, 2013
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials
CLL Trialists' CollaborativeGroup
Journal of the National Cancer Institute 91 (10), 861-868, 1999
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
SEM Herman, CU Niemann, M Farooqui, J Jones, RZ Mustafa, A Lipsky, ...
Leukemia 28 (11), 2188-2196, 2014
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ...
Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018
15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL 2): prolonged remissions without survival plateau
CW Eskelund, A Kolstad, M Jerkeman, R Räty, A Laurell, S Eloranta, ...
British journal of haematology 175 (3), 410-418, 2016
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
A Hadzidimitriou, A Agathangelidis, N Darzentas, F Murray, ...
Blood, The Journal of the American Society of Hematology 118 (11), 3088-3095, 2011
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line …
CH Geisler, A Kolstad, A Laurell, R Räty, M Jerkeman, M Eriksson, ...
Blood, The Journal of the American Society of Hematology 115 (8), 1530-1533, 2010
Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study
F Pandolfi, TP Loughran Jr, G Starkebaum, T Chisesi, T Barbui, WC Chan, ...
Cancer 65 (2), 341-348, 1990
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network
E Hoster, W Klapper, O Hermine, HC Kluin-Nelemans, J Walewski, ...
J Clin Oncol 32 (13), 1338-1346, 2014
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Dreyling, C Geisler, O Hermine, HC Kluin-Nelemans, S Le Gouill, ...
Annals of Oncology 25, iii83-iii92, 2014
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20